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Background: The MedSeq Project is a randomized clinical trial developing approaches to assess the impact of
integrating genome sequencing into clinical medicine. To facilitate the return of results of potential medical
relevance to physicians and patients participating in the MedSeq Project, we sought to develop a reporting
approach for the effective communication of such findings.
Methods: Genome sequencing was performed on the Illumina HiSeq platform. Variants were filtered, interpreted,
and validated according to methods developed by the Laboratory for Molecular Medicine and consistent with
current professional guidelines. The GeneInsight software suite, which is integrated with the Partners HealthCare
electronic health record, was used for variant curation, report drafting, and delivery.
Results: We developed a concise 5–6 page Genome Report (GR) featuring a single-page summary of results of
potential medical relevance with additional pages containing structured variant, gene, and disease information along
with supporting evidence for reported variants and brief descriptions of associated diseases and clinical implications.
The GR is formatted to provide a succinct summary of genomic findings, enabling physicians to take appropriate steps
for disease diagnosis, prevention, and management in their patients.
Conclusions: Our experience highlights important considerations for the reporting of results of potential medical
relevance and provides a framework for interpretation and reporting practices in clinical genome sequencing.
Keywords: Clinical genome sequencing, Incidental findings, MedSeq Project, Clinical report formattingBackground
Whole exome and genome sequencing, hereafter referred
to as genomic sequencing (GS) are rapidly expanding into
the clinical arena [1,2]. As the cost of GS declines and the
performance and clinical utility of the technologies
improve [3-6], it is likely that most clinical sequencing
tests will be replaced by next generation sequencing of* Correspondence: hrehm@partners.org
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indications with extensive genetic heterogeneity.
While the expansion of GS into clinical care is promising
for the diagnosis and treatment of patients with genetic
disorders, and eventually the screening of healthy individuals,
GS produces an extensive amount of sequencing data
which must be analyzed, filtered, interpreted, and reported
upon by the clinical laboratory. In contrast to traditional
genetic tests which typically report back a limited set of
variants conditioned on prior clinical or family data and
with relatively clearly defined supporting evidence, clinical
reports resulting from GS analyses contain many variants
each with disparate supporting evidence associated
with a broad range of diseases, and a wide set of pretestntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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this complex information and determine the relevant
inferences for the care of their patient. This requires
a nuanced understanding of the underlying rationale
for GS, technical aspects of the testing and its primary
interpretation, and knowledge of how to define (or refine)
the probabilistic nature of the genotype in the context of
the individual patient or family. In many instances, this
understanding is also dependent on mechanistic insight
into the relevant human biology. Unfortunately, many
physicians in non-genetic specialties lack fundamental
genetic knowledge and are uncomfortable interpreting
genetic test results, which may result in misinterpretation
and inaccurate patient counseling [7-10]. Similarly, these
non-specialists are often unaware of the phenotypic
nuances and pathobiological knowledge necessary to
optimize the interpretation of genotypes and realize
the full potential of GS in clinical care. Together, these limi-
tations increase the risk that physicians may over-interpret
GS results, leading to unnecessary followup testing and/or
inaccurate diagnoses; or under-interpret GS results, leading
to inadequate patient management.
In order to facilitate the communication of results of
potential medical relevance to a broad range of physicians,
laboratories must decide upon the level of evidence
required for variants to be returned on the report. Some
laboratories may choose to report all classified variants,
even variants of uncertain significance with little evidence
supporting pathogenicity, resulting in massive reports. In
this situation, physicians may be overwhelmed by lengthy
reports and experience difficulty identifying which variants
are most important with respect to the care of their
patient. In contrast, laboratories may restrict reports to
pathogenic variants with a definitive association with
disease and a narrow definition of actionability. However
few variants meet this level of evidence and this approach
risks the omission of many variants whose relevance is
dependent on the clinical context. Indeed, some variants
may turn out to be clinically relevant as further clinical
data are gathered. Thus, an intermediate approach may be
required to facilitate the communication of results of
potential medical relevance to a broad range of physicians.
Moreover, it will be vital to communicate the requisite
information on potential disease or risk associations for
each reported variant to allow physicians to interpret GS
test results in the relevant clinical context, to orchestrate
additional phenotyping, or to refer the patient to an
appropriate specialist.
To promote the understanding and utility of GS data,
we have developed a Genome Report (GR) for the return
of findings of potential medical relevance for individuals
participating in the MedSeq Project, a randomized
clinical trial assessing the impact of GS in two patient
populations — healthy primary care patients and patientswith cardiomyopathy of suspected genetic etiology. The
GR is a concise 5–6 page genome-scale report featuring a
succinct front page summary of findings of potential med-
ical relevance with additional pages containing structured
variant, gene, and disease information as well as supporting
evidence and disease and health impact summaries.
Methods
MedSeq Project rationale and study design
The MedSeq Project is a randomized clinical trial that is
testing approaches for evaluating and reporting of GS data
and assessing the impact of integrating GS into primary
care and cardiology settings. To achieve these goals, the
MedSeq Project is recruiting 10 primary care physicians,
each with 10 of their generally healthy patients and
10 cardiologists, each with 10 of their cardiomyopathy
patients, for total of 200 participants. Half of the partici-
pants are being randomized to the GS arm. The physicians
of each patient enrolled in the GS arm receive a GR
communicating genetic findings of potential medical
relevance. Interviews and survey instruments for both
physicians and patients are being used to determine
the impact of GS on attitudes, behaviors, healthcare
utilization, and decision-making. A detailed report of
the goals, protocol, and methods in the MedSeq Project is
summarized elsewhere [11].
Genome sequencing
GS is performed by the CLIA-certified, CAP-accredited
Illumina Clinical Services Laboratory (San Diego, CA)
using paired-end 100 base pair reads on the Illumina
HiSeq platform [12]. Genomes are sequenced to at least
30X mean coverage and ≥ 95% of bases are sequenced to
at least 8X coverage. Lossless BAM files containing
sequence alignment and variant calling data are returned
to the Laboratory for Molecular Medicine (LMM) via an
encrypted portable hard drive for further analysis.
Clinical bioinformatics pipeline
Lossless BAM files are converted to FASTQ format to
obtain sequence read data and reads are realigned to
the NCBI reference sequence (GRCh37) using the
Burrows-Wheeler Aligner 0.6.1-r104 [13]. Variant calls
are made using the Genomic Analysis Tool Kit (GATK)
version 2.3-9-gdcdccbb [14] for all positions with ≥8X
coverage. Variant annotation is derived from ALAMUT
HT version 1.1.2, Variant Effect Predictor version 2.6 and
the LMM’s GeneInsight laboratory database. Annotated
variants are subsequently filtered to identify: (1) variants
with a minor allele frequency (MAF) <5% in European
American (EA) or African American (AA) chromosomes
from the NHLBI Exome Sequencing Project (ESP;
http://evs.gs.washington.edu/EVS/) classified as disease
causing (DM) or possible disease causing mutations
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or as Pathogenic or Likely pathogenic by the LMM;
(2) nonsense, frameshift, and canonical splice-site
(+/−1,2) variants with a MAF <1% in EA or AA chro-
mosomes from the NHLBI ESP from a list of 4,631
disease-associated genes curated by expert review of
many sources of gene-disease relationships (Online
Mendelian Inheritance in Man (OMIM),ClinVar, etc.;
http://www.iccg.org/iccg-member-toolbox/databases-tools/
medial-exome-gene-list) and (3) pharmacogenomic vari-
ants for metformin (C11orf65 rs11212617), clopidogrel
(CYP2C19 rs12248560, rs4244285, rs4986893, rs28399504,
rs41291556, rs72552267, rs72558186, rs56337013), warfarin
(CYP2C9 rs1057910, rs1799853, rs7900194, rs9332131,
rs28371685, rs28371686 and VKORC1 rs9923231), sim-
vastatin (SLCO1B1 rs4149056), and digoxin (ABCB1
rs1045642) metabolism. The disease-associated gene list is
iteratively refined as gene-disease association information
is curated. In addition, blood group antigens are predicted
through a parallel pipeline as noted below.
Variant classification
The principles we follow for the classification of potential
Mendelian disease-causing variants have been previously
described [16] and involve analysis of multiple lines of
evidence including allele frequency, genetic and functional
evidence from peer-reviewed scientific literature, and
computational analysis (nucleotide and amino acid
conservation, domain localization, missense pathogenicity
prediction algorithms, and splice site prediction algorithms).
Predicted loss-of-function (LOF) variants are evaluated in
the context of review of known gene-disease associations
and a determination of whether LOF is an established
mechanism of disease for the gene in question. Each variant
is classified according to American College of Medical
Genetics and Genomics (ACMG) recommendations
[17] and LMM criteria [16]. Several variants required
deliberation by MedSeq Project team members (including
clinical geneticists, molecular geneticists, genetic counselors,
and bioinformaticians) in order to assign a final
classification. The LMM uses a five tier classification
system which includes the following classifications:
benign, likely benign, uncertain significance, likely
pathogenic, and pathogenic. In addition, a subset of
uncertain significance variants are further subclassified
into “uncertain significance: favor benign” or “uncertain
significance: favor pathogenic”. With the exception of
pharmacogenomic alleles and blood group antigens, only
those variants with substantial evidence for causing or
contributing to Mendelian genetic disease are reported.
This includes all pathogenic, likely pathogenic, and
uncertain significance: favor pathogenic variants. All
reported disease-associated variants are confirmed via
Sanger sequencing before reporting. Variants are fullyreassessed when identified in a new case and the last assess-
ment was completed over 1 year ago for pathogenic vari-
ants or over 6 months ago for likely pathogenic variants
and variants of uncertain significance. Likely benign and
benign variants are not fully reassessed unless requested by
a clinician. However, all variants in the categories of likely
pathogenic, uncertain significance, and likely benign are
briefly reevaluated before each reporting through a quick
search of online variant databases (ClinVar, HGMD, ESP,
1000G, ExAC) to ensure no new data has been reported.
Pharmacogenomic analysis
A set of 18 variants associated with the metabolism of 5
drugs (see above) commonly used in the treatment of
primary care and cardiology patients were selected for
inclusion in the GR from PharmGKB Clinical Annotation
Levels of Evidence Class I and Class II variants [18].
Additional PharmGKB Class I variants are also made
available for validation and reporting if requested by the
physician. All pharmacogenomic variant bases were geno-
typed using GATK version 2.3-9-gdcdccbb [14] and con-
firmed via Sanger sequencing or Illumina HumanOmni2.5
array (San Diego, CA) before reporting.
Blood group prediction and serological confirmation
Red blood cell (RBC) and human platelet antigens (HPAs)
are predicted using GS data. For all 45 RBC and 6 HPA
genes, GATK is used to genotype each exon along with the
first and last 10 bases of each intron. A custom prediction
algorithm is then used to semi-automatically predict RBC
and platelet antigens, followed by manual verification in the
BAM alignment files for all antigens listed on the GR [19].
Variant curation and reporting
Variant information, including classifications, interpreta-
tions, and associated references are stored in an internal
laboratory knowledge base using the GeneInsight soft-
ware suite [20]. Approved variant classifications with
supporting evidence descriptions are submitted to the
ClinVar database to support community knowledge sharing
[21]. GRs are drafted and finalized using GeneInsight Lab
and electronically delivered to physicians participating in
the MedSeq Project via GeneInsight Clinic. Changes
to variant classification in GeneInsight Lab resulting
from new data are automatically communicated to
participating physicians via an email notification that links
them to a patient report update within the GeneInsight
Clinic application for subsequent decision support [22].
Development of the genome report
The GR presented herein was developed by a team of
MedSeq Project investigators including physicians from
genetic and non-genetic specialties, genetic counselors,
molecular geneticists, and bioinformaticians. Prior to
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was evaluated by a multi-disciplinary advisory committee
also consisting of physicians from genetic and non-genetic
specialties, genetic counselors, molecular geneticists,
bioinformaticians, bioethicists, patient advocates, and
biotechnology industry leaders. Revised versions of the
GR were subsequently reviewed with primary care
physicians who were considering participation in MedSeq
Project and underwent further changes intended to
maximize clarity and utility (Additional file 1).
Results
Analysis and interpretation of genomes
Each patient enrolled in the sequencing arm of the
MedSeq Project receives a GR detailing findings of poten-
tial medical relevance including monogenic disease risk,
carrier risk for recessive disorders, pharmacogenomic
associations for commonly used medications, and a blood
group antigen summary. The MedSeq Project has adopted
an approach for returning findings of potential medical
relevance that attempts to strike a balance between over
and under reporting of variants. Instead of restricting
reports to a very narrow set of disease-associated variants
such as those found in the 56 genes recommended by the
American College of Medical Genetics and Genomics
(ACMG) [23], we have chosen to include additional analysis
of many genes of potential medical relevance. This includes
reporting of any variant with evidence supporting a
causal role in a Mendelian genetic disease or representing
carrier status for such diseases. The average genome-wide
coverage ≥8X for the first 20 sequenced MedSeq ProjectFigure 1 MedSeq Project variant analysis workflow. M (million), Genomcases (12 primary care arm and 8 cardiomyopathy arm)
was 95.5% and patients had 3.4 to 5.3 million variants
compared to the reference genome. Variants are filtered
and analyzed via a comprehensive variant assessment
process evaluating allele frequency, computational
predictions, and genetic and functional evidence from
peer-reviewed scientific literature (Figure 1) [16]. Each
variant is classified according to LMM criteria [16],
consistent with ACMG recommendations [17].
A total of 381 unique variants were manually assessed
and classified for the first 20 MedSeq Project cases
(251 ascertained via the HGMD filter, 110 ascertained
via the LOF filter, 20 ascertained via both filters).
After assessment, 168 (44%) of these variants were
classified as benign or likely benign, 168 (44%) were
classified as uncertain significance (including 5 classified
as uncertain significance: favor pathogenic), and 45
(12%) were classified as likely pathogenic or pathogenic
(Figure 2a). Similar to previously published studies
[6,24,25], we found that very few variants with a purported
disease association in HGMD met our criteria for patho-
genicity. Out of 271 variants assessed that were categorized
as DM or DM? in HGMD, only 22 (8%) were classified as
likely pathogenic or pathogenic, and all but 1 of these had a
DM categorization (Figure 2b).
A total of 80 unique variants from the first 20 MedSeq
Project cases were selected for Sanger confirmation. Of
these, 68 (85%) were confirmed, 1 (1%) was confirmed but
with differing zygosity, and 11 (14%) were determined to be
false positive. All false positive variants were either indels
with low genotyping quality scores, or variants residinge Report (GR), variant of uncertain significance (VUS).
Figure 2 Variant classifications from 20 genomes (a). A total of 381 unique variants were assessed and classified after filtration (b) HGMD
classification comparison. Disease causing mutation (DM), likely disease causing mutation (DM?), loss-of-function (LOF).
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deliberation by the MedSeq Project team, 48/69 (69%) of
the unique Sanger-confirmed variants were returned to
the first 20 MedSeq Project participants (Table 1). These
included 39 variants associated with carrier status for
recessive disorders, 8 variants for monogenic disease
risk (5 of which were identified in individuals from
the cardiomyopathy arm and assumed to be responsible
for these individual’s cardiomyopathy pending definitive
analysis within the family) and 1 variant that conferred
both carrier status and monogenic disease risk. The 21
variants that were Sanger confirmed but not reportedwere pursued for confirmation because the primary
reviewer thought there was potential for being reported
but after review by a board-certified laboratory geneticist
and/or the full MedSeq Project committee, these variants
did not meet the pathogenicity evidence level and/or
clinical relevance threshold for return.
An entire genome summarized on a single page
In order to communicate findings of potential medical
relevance to MedSeq Project physicians, we developed a
GR designed to convey complex genomic data in a succinct
and effective manner to the non-genetic specialist physician
Table 1 Reported findings of potential medical relevance for the first 20 MedSeq genomes
Gene Nucleotide Protein Disease Classification Inheritance Report section Filter
SPATA7 c.94 + 2 T > C p.? Leber congenital amaurosis LP AR Carrier Risk LOF
ERCC5 c.3238C > T p.Arg1080X Xeroderma pigmentosum LP AR Carrier Risk LOF
COL7A1 c.7557 + 1G > T p.? Epidermolysis bullosa dystrophica LP AR Carrier Risk LOF
C2 c.841_849 + 19del p.Val281_Arg283del C2 deficiency LP AR Carrier Risk LOF
MYO7A c.5648G > A p.Arg1883Gln Usher syndrome type I LP AR Carrier Risk HGMD
NAGA c.479C > G p.Ser160Cys Alpha-N-acetylgalactosaminidase deficiency LP AR Carrier Risk HGMD
KCNQ1 c.826delT p.Ser276ProfsX13 Jervell and Lange-Nielsen syndrome LP AR Carrier Risk LOF
LAMA2 c.5563-2A > G p.? Congenital muscular dystrophy type IA LP AR Carrier Risk LOF
SP110 c.877A > T p.Lys293X Hepatic veno-occlusive disease with immunodeficiency LP AR Carrier Risk LOF
ARSB c.1450A > G p.Arg484Gly Mucopolysaccharidosis type VI LP AR Carrier Risk HGMD
BEST1 c.602 T > C p.Ile201Thr Autosomal recessive bestrophinopathy LP AR Carrier Risk HGMD
ACOX1 c.1851delT p.Gly618AlafsX24 Peroxisomal acyl-CoA oxidase deficiency LP AR Carrier Risk LOF
LIFR c.2074C > T p.Arg692X Stuve-Wiedemann syndrome LP AR Carrier Risk LOF
PAH c.842 + 5G > A p.? Phenylketonuria LP AR Carrier Risk HGMD, LOF
MMACHC c.271dupA p.Arg91LysfsX14 Methylmalonic aciduria and homocystinuria cblC type P AR Carrier Risk LOF
CFTR c.3846G > A p.Trp1282X Cystic fibrosis P AR Carrier Risk HGMD, LOF
PFKM c.237 + 1G > A p.? Glycogen storage disease 7 P AR Carrier Risk HGMD, LOF
CUBN c.6928_6934del p.Glu2310CysfsX3 Imerslund-Gräsbeck syndrome P AR Carrier Risk LOF
DUOX2 c.3847 + 2 T > C p.? Hypothyroidism P AR Carrier Risk LOF
ABCA4 c.5882G > A p.Gly1961Glu Stargardt disease P AR Carrier Risk HGMD
MPO c.2031-2A > C p.? Myeloperoxidase deficiency P AR Carrier Risk HGMD
SERPINA1 c.1096G > A p.Glu366Lys Chronic obstructive pulmonary disease P AR Carrier Risk HGMD
USH2A c.1214del p. Asn405IlefsX3 Usher syndrome type II P AR Carrier Risk LOF
CLRN1 c.528 T > G p.Tyr176X Usher syndrome type III P AR Carrier Risk HGMD, LOF
CYP1B1 c.171G > A p.Trp57X Primary congenital glaucoma P AR Carrier Risk LOF
NLRP7 c.337_338insG p.Glu113GlyfsX7 Recurrent hydatidiform mole P AR Carrier Risk LOF
BTD c.1330G > C p.Asp444His Biotinidase deficiency P AR Carrier Risk HGMD
SPG7 c.1529C > T p.Ala510Val Spastic paraplegia type 7 P AR Carrier Risk HGMD
PYGL c.25_44dup p.Ser15ArgfsX21 Glycogen storage disease 6 P AR Carrier Risk LOF
WFS1 c.124C > T p.Arg42X Wolfram syndrome P AR Carrier Risk LOF
CYP1B1 c.1103G > A p.Arg368His Primary congenital glaucoma P AR Carrier Risk HGMD
TCIRG1 c.1674-1G > A p.? Infantile malignant osteopetrosis P AR Carrier Risk HGMD, LOF














Table 1 Reported findings of potential medical relevance for the first 20 MedSeq genomes (Continued)
RAPSN c.264C > A p.Asn88Lys Congenital myasthenic syndrome P AR Carrier Risk HGMD
TCTN2 c.1877 T > A p.Leu626X Joubert syndrome P AR Carrier Risk LOF
DUOX2 c.2895_2898del p.Phe966SerfsX29 Congenital hypothyroidism P AR Carrier Risk LOF
HFE c.845G > A p.Cys282Tyr Hereditary hemochromatosis P AR Carrier Risk HGMD
GJB2 c.109G > A p.Val37Ile Hearing loss P AR Carrier Risk HGMD
RAB27A c.259G > C p.Ala87Pro Familial hemophagocytic lymphohistiocytosis VUS:FP AR Carrier Risk HGMD
CNGA3 c.1669G > A p.Gly557Arg Achromatopsia VUS:FP AR Carrier Risk HGMD
KCNQ1 c.826delT p.Ser276ProfsX13 Romano Ward syndrome LP AD Monogenic LOF
MYBPC3 c.3742-3759dup p.Gly1248_Cys1253dup Hypertrophic cardiomyopathy LP AD Monogenic HGMD
MYBPC3 c.2827C > T p.Arg943X Hypertrophic cardiomyopathy P AD Monogenic HGMD, LOF
MYBPC3 c.772G > A p.Glu258Lys Hypertrophic cardiomyopathy P AD Monogenic HGMD
LHX4 c.452-2A > C p.? Combined pituitary hormone deficiency P AD Monogenic LOF
PTPN11 c.1403C > T p.Thr468Met LEOPARD syndrome P AD Monogenic HGMD
PPOX c.199delC p.Leu67X Variegate porphyria P AD Monogenic HGMD, LOF
MYH7 c.1987C > T p.Arg663Cys Hypertrophic cardiomyopathy P AD Monogenic HGMD
ARSE c.410G > C p.Gly137Ala Chondrodysplasia punctata VUS:FP XL Monogenic HGMD
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Additional file 4). The first page of the GR summarizes all
findings including findings related to the indication for
testing (for cardiomyopathy patients), monogenic disease
risk, carrier risk for recessive disorders, pharmacogenomic
results, and a blood group antigen summary on a single
page (Figure 3). The GR result summary includes a
description of genome coverage and the total number
of variants identified compared to a reference genome,
providing the physician with a high-level overview of the
quality and complexity of their patient’s GS data. Results
relevant to indication for testing (for cardiomyopathy
patients) and other variants of medical significance
(incidental findings) are clearly delineated and each is
supplemented with the disease name, inheritance, a
brief phenotype description, the Human GenomeFigure 3 Example Genome Report result summary.Organization (HUGO)-approved gene name, a variant
description in Human Genome Variation Society (HGVS)
nomenclature, and variant classification in a simple
tabular format. When applicable, milder and/or low
penetrant phenotypes that have been reported in associ-
ation with carrier status for recessive disorders are also
noted. For example, individuals who are carriers for
pathogenic variants in the Wolfram syndrome 1 (WFS1)
gene, may exhibit low frequency sensorineural hearing loss
and/or diabetes mellitus [26-28]. A summary of pharmaco-
genomic associations for five commonly administered
drugs are also displayed in a tabular format, describing
predicted dose requirements, drug response, or the risk of
adverse events in straightforward qualitative language.
Finally, predicted ABO Rh blood types are returned along
with any red blood cell (RBC) or human platelet antigens
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ling risk prediction for blood transfusion complications
and/or awareness of desirable blood donor status for rare
blood types. Physicians are directed to subsequent
pages of the report to obtain more detailed information
supporting the result summary.
Supplementing reports with detailed variant, gene, and
disease information
Due to the vast array of diseases, genes, and variant types
that could be returned from GS, we sought to balance the
need for a high level summary that enables quick viewing,
with the importance of providing sufficient detail and
evidence to support reported results. Therefore, we expand
upon the single page GR summary with a detailed variant
information section featuring structured tables with
RefSeq transcript, variant frequency, disease prevalence,
and if applicable, carrier frequency (Additional file 2,
Additional file 3 and Additional file 4). Providing transcript
information and a clear variant description is essential for
an unequivocal definition of the variant. Reporting the
population carrier frequency for recessive disorders, if
known, allows physicians to counsel individuals on the risk
of having an affected child with an existing or future repro-
ductive partner. Variant interpretations are included for
each variant describing the evidence collected during the
variant assessment process and providing a rigorous ration-
ale for the variant classification. These evidence-based vari-
ant summaries are then submitted to the ClinVar database
to provide transparent rationales for variant interpretations.
Disease information summaries outlining common
phenotypes and natural history associated with the disease
are extracted from GeneReviews and Orphanet abstracts
[29,30]. Uniform resource locators (URLs) for relevant
online resources are also provided, allowing physicians to
consult appropriate materials. Familial risk information is
also described to provide physicians and patients with an
explanation of the inheritance pattern and potential risk
implications for offspring and biological family members.
Literature references are cited for each variant with a full
list of references at the end of the report.
Pharmacogenomic results are supplemented with tabular
supporting information (Additional file 2, Additional file 3
and Additional file 4). The drug and indication is provided
along with a summary of the dose requirement or risk of
adverse effects. For each drug, variants evaluated are
described using HGVS nomenclature, rsID, and PharmGKB
haplotype, when applicable. A detailed interpretation
is provided for each drug and genotype frequencies
are provided to allow physicians to contextualize the
prevalence of the patient’s pharmacogenetic diplotype
compared to the general population. Literature references
are cited for each pharmacogenomic association with a
full reference list at the end of the report.The ABO Rh blood type and rare antigens summary
are supplemented by additional blood group informa-
tion provided in a tabular format (Additional file 2,
Additional file 3 and Additional file 4). The presence
or absence of a series of a selective number of 57
RBC antigens and all 33 platelet antigens are provided
for each patient. The discussion also highlights when
an individual is predicted to lack a highly prevalent
antigen, making them at risk for transfusion-related
events, when an individual lacks an antigen that may
impact susceptibility to certain diseases, or when an indi-
vidual lacks a highly immunogenic antigen, making them
a good candidate for whole blood or platelet donation.
Conveying methodology and limitations of genome
sequencing
Laboratories offering GS employ a multitude of strategies
for their bioinformatics, interpretation, and reporting
pipelines [31,32]. In addition to providing required test
methodology on the report, we also include a concise
description of our analysis and interpretation process to
promote understanding of the sequencing and interpret-
ation pipeline, thereby allowing physicians to compare
approaches among GS tests.
While our GS test currently offers at least 30X mean
coverage across the genome and ≥ 95% of bases are
sequenced to at least 8X coverage, there are some
limitations to GS that the MedSeq Project team was
tasked with conveying to physicians. First, certain
types of variation are currently not reliably detected via
GS including structural variants, triplet repeat expansions,
copy number variants, uniparental disomy, and epigenetic
changes. Therefore, the definitive absence of a pathogenic
variant in certain disease-associated genes cannot always
be reliably inferred depending on the spectrum of causa-
tive variation. Secondly, coverage of disease-associated
genes may be insufficient to detect all variants. To address
this limitation, we have opted to provide physicians with
coverage information for any genes upon request and to
include coverage information for established indication-
associated genes for individuals from the cardiomyopathy
arm of the study (Additional file 2 and Additional file 3).
Finally, not all disease-associated genes have been identi-
fied and the clinical significance of variants in many genes,
even those already associated with disease, remains
elusive. The limitations described above are clearly
listed on the first page and on the limitations section
of each MedSeq Project GR.
Delivery of genome reports
Our GeneInsight software suite [20] is used to store variant
classifications, interpretations, diseases, and associated
references for each reported variant. Reports are drafted
using a custom GR reporting template and finalized reports
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(PDF) to physicians participating in the MedSeq Project via
GeneInsight Clinic (GIC), a physician interface that
facilitates report viewing and download as well as updates
to reports over time [22]. Electronically transmitted
reports also contain structured variant data in an XML
packet that is represented in the patient’s electronic health
record to enable clinical decision support in the future.
Discussion
The reporting of findings of potential medical relevance
from GS is rapidly expanding into the clinical arena.
However, little attention has been focused on how to
effectively communicate GS results to physicians. The
MedSeq Project has adopted an experimental approach for
the return of results of potential medical relevance to study
the impact of introducing a variety of different categories of
variant data into the clinical care setting. To convey this
range of results to the MedSeq Project participants, we
have created a physician-oriented genomics report featuring
a concise single-page summary of genome-wide findings of
potential medical relevance with clearly delineated sections
for highly-penetrant monogenic disease risk, carrier status
for recessive disorders, pharmacogenomic associations,
and blood group antigens. Preliminary analysis of the
first 18 audio-recorded GR disclosure sessions indicates
that genetic and primary care physicians are generally
able to synthesize essential report information and
effectively communicate genetic disease risk to their
patients [33-36].
The variant interpretation process required for clinical
analysis of whole genome sequence is an arduous endeavor
that begins with automated filtration, but always requires
manual curation of publications and careful synthesis of
available data. Members of the MedSeq Project team,
including clinical geneticists, molecular geneticists, genetic
counselors, and bioinformaticians, gather weekly to
discuss variant evidence. We have found these discussions
invaluable for reaching a consensus on the interpretation
of difficult variants. Each genome analyzed thus far has
contained pathogenic variants in genes and diseases
unfamiliar to our clinical laboratory, further adding to the
challenge of genomic interpretation. Our experience
reinforces the notion that broad data sharing, including
gene and variant interpretations, will be a prerequisite to
effectively curate thousands of genes and the variation
within them in order to improve the interpretation process
and achieve consensus on the classification of variants.
Community efforts supporting the deposition of variant
data into centralized locations such as the ClinVar database
[21] will be critical to the successful incorporation of GS
into clinical medicine. The MedSeq Project will further
support these efforts by depositing all generated variant
classifications into the ClinVar database.The GR reporting template presented here will continue
to evolve as the clinical genomics community strives to
promote the understanding and utility of GS data. Moving
forward, we plan to incorporate hyperlinks to interfaces
with supporting resources such as the Online Mendelian
Inheritance in Man (OMIM), GeneReviews, PubMed, and
disease-specific resources. Future iterations may include
the addition of ancestry information and common disease
risk alleles. In addition, the scope of genome analysis for
each patient may evolve as an individual patient’s medical
history and clinical situation develop. For example,
additional pharmacogenomic results may be added
and reinterpretation of genome data may be warranted if
new symptoms arise or previously unappreciated familial
risk is uncovered.
In the current genetic testing paradigm, clinical laborator-
ies provide physicians with genetic results and physicians
are in turn responsible for incorporating these results into
care plans for their patients. One of the greatest barriers to
integrating GS into clinical care is the limited amount of
objective data regarding the best course of action for almost
any genetic finding in the context of sequence from an
entire genome. Physicians may grapple with ordering
additional diagnostic tests for their patients to uncover
potential disease-related phenotypes, and whether
additional family members should be evaluated [2]. While
this is not dissimilar to the problems encountered when
any form of clinical testing moves from a narrow indication
to broad clinical use, the sheer scale of the uncertainty is
many orders of magnitude greater than for any prior
scenario. In the future, it is clear that collaboration on a
massive scale between clinical laboratories, clinical geneti-
cists, genetic counselors, bioinformaticians, and physicians
will be necessary to deconvolute the relationships between
genotype and health or disease. A comprehensive redesign
of the iterative process of test ordering, result report-
ing, and secondary interpretation will be necessary to
provide integrated guidance and care recommendations
for patients with genetic findings warranting further
investigation. These steps will be critical as the results
found in genome sequence reports will routinely cross
the boundaries between existing silos of professional
expertise.
Conclusions
In order to advance the incorporation of GS data into
clinical care, we have created a concise clinical GR that
outlines findings of potential medical relevance, enabling
physicians to counsel patients regarding the health and
reproductive implications of their genome sequences.
Our experience highlights important considerations in
the reporting of findings of potential medical relevance
and provides a framework for evolving interpretation
and reporting practices in clinical GS.
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